Breast cancer gene therapy trials

Another FDA apvproved diagnosis test is MammaPrint to assess the risk of breast tumor and this will help to decide the effectiveness of chemotherapy on the patients, (van t Veer et al, 2002) The assay uses the fresh tissue to study the Amsterdam 70-gene breast cancer gene signature by microarray analysis, (van t Veer et al, 2002) Readers interested in this test can also obtain more information about the MIND ACT trial (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemo Therapy) in the p>ap)er by Cardoso et al. (Cardoso et al, 2008)... 

MEK inhibitor selumetinib (AZD6244, AstraZeneca).94,95 In 2010, BKM120 advanced to a Phase I II trial as a combination therapy with trastuzumab in breast cancer patients. A second compound, BYL719, began a Phase II trial in late 2010 in patients with solid tumors with a mutation of the PIK3CA gene however, the properties and biological activities of this compound have yet to be disclosed. 

---